Claim Missing Document
Check
Articles

Found 33 Documents
Search

The Association Between Haloperidol and Clozapine and The Risk of Hyperglycaemia in Patients with Schizophrenia Martanty Aditya; Godeliva Adriani Hendra; Rina Setyowati
Jurnal Farmasi Ma Chung: Sains, Teknologi, dan Klinis Komunitas Vol. 4 No. 1 (2026): Jurnal Farmasi Ma Chung: Sains, Teknologi, dan Klinis Komunitas
Publisher : Program Studi Farmasi, Universitas Ma Chung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33479/jfmc.v4i1.105

Abstract

First- and second-generation antipsychotics such as haloperidol and clozapine are treatment options for schizophrenia; however, both have the potential for metabolic side effects, including hyperglycemia. This study aimed to analyse the association between using haloperidol or clozapine, either alone or together, and the occurrence of hyperglycemia in patients with schizophrenia. The research used an observational design with a cross-sectional study and retrospective data from 154 medical records of schizophrenia patients. The study was conducted at Dr. Radjiman Wediodiningrat Psychiatric Hospital outpatient clinic, Lawang, from January to March 2025. Data were analysed using the chi-square test and odds ratio with RStudio 2024. The results showed that most patients received clozapine alone or with other medications (70.78%). A significant association was found between clozapine use and male sex (p = 0.014) as well as the 17–40 age group (p = 0.001). Haloperidol use was linked to an increased risk of elevated creatinine levels (p = 0.026). However, there was no significant link between the type of therapy and the risk of hyperglycemia (OR = 1.243; 95% CI: 0.097–66.819). Levels of SGOT (p = 0.913), SGPT (p = 0.258), and urea (p = 1.000) stayed within normal limits in both treatment groups. In summary, clozapine may carry a slightly higher but statistically insignificant risk of causing hyperglycemia. Overall, treatment with haloperidol or clozapine appears safe concerning liver and kidney function, as indicated by normal SGOT, SGPT, and urea levels.
Analisis Hubungan Hambatan Terhadap Kepatuhan pada Pasien Diabetes Melitus Rafica Tri Oktaviasari; Godeliva Adriani Hendra; Dhanang Prawira Nugraha
Jurnal Farmasi Ma Chung: Sains, Teknologi, dan Klinis Komunitas Vol. 3 No. 2 (2025): Jurnal Farmasi Ma Chung: Sains, Teknologi, dan Klinis Komunitas
Publisher : Program Studi Farmasi, Universitas Ma Chung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33479/jfmc.v3i2.86

Abstract

Diabetes Melitus adalah Kondisi yang ditandai dengan kadar glukosa darah tinggi yang terus-menerus akibat produksi insulin yang tidak mencukupi atau gangguan kinerja insulin. Tim peneliti di Rumah Sakit Lavalette, Malang, bertujuan untuk mempelajari tantangan yang dihadapi pasien diabetes melitus dan seberapa baik mereka mematuhi rencana perawatan mereka. Desain penelitian ini menggunakan Cross-Sectional dengan pengambilan data secara prospektif yaitu melalui wawancara kuesioner kepada pasien diabetes melitus pada pasien diabetes melitus di poli rawat jalan Rumah Sakit Lavalette Malang pada bulan Mei - Juni 2023. Sampel yang memenuhi kriteria yaitu sejumlah 155 pasien, menggunakan lembar pengumpul data dan kuesioner yaitu Medication Adherence Rating Scale 5 (MARS-5) serta Diabetes Obstacle Quetionnare (DOQ) kemudian dianalisis menggunakan Uji Chi Square. Hasil penelitian ini pada penggunaan OAD oral 30 pasien dan kombinasi 125 pasien DM, analisis hubungan hambatan terhadap kepatuhan pasien DM yaitu hambatan pengobatan p-value 0,008, hambatan pengobatan sendiri p-value 0,007, hambatan pengetahuan dan keyakinan p-value 0,001, hambatan mengatasi diabetes p-value 0,000. Adapun analisis hubungan sosio demografi dengan kepatuhan yaitu pada penggunaan obat antidiabetes. Kesimpulan dari penelitian ini yaitu terdapat hubungan antara hambatan dengan kepatuhan pasien DM, tidak terdapat hubungan antara sosio jenis kelamin, IMT, komorbid, lama menderita, riwayat keluarga, pekerjaan, tingkat pendidikan, perokok kecuali usia yang terdapat hubungan dengan kepatuhan pasien DM.
The Association Between Haloperidol and Clozapine and The Risk of Hyperglycaemia in Patients with Schizophrenia Martanty Aditya; Godeliva Adriani Hendra; Rina Setyowati
Jurnal Farmasi Ma Chung: Sains, Teknologi, dan Klinis Komunitas Vol. 4 No. 1 (2026): Jurnal Farmasi Ma Chung: Sains, Teknologi, dan Klinis Komunitas
Publisher : Program Studi Farmasi, Universitas Ma Chung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33479/jfmc.v4i1.105

Abstract

First- and second-generation antipsychotics such as haloperidol and clozapine are treatment options for schizophrenia; however, both have the potential for metabolic side effects, including hyperglycemia. This study aimed to analyse the association between using haloperidol or clozapine, either alone or together, and the occurrence of hyperglycemia in patients with schizophrenia. The research used an observational design with a cross-sectional study and retrospective data from 154 medical records of schizophrenia patients. The study was conducted at Dr. Radjiman Wediodiningrat Psychiatric Hospital outpatient clinic, Lawang, from January to March 2025. Data were analysed using the chi-square test and odds ratio with RStudio 2024. The results showed that most patients received clozapine alone or with other medications (70.78%). A significant association was found between clozapine use and male sex (p = 0.014) as well as the 17–40 age group (p = 0.001). Haloperidol use was linked to an increased risk of elevated creatinine levels (p = 0.026). However, there was no significant link between the type of therapy and the risk of hyperglycemia (OR = 1.243; 95% CI: 0.097–66.819). Levels of SGOT (p = 0.913), SGPT (p = 0.258), and urea (p = 1.000) stayed within normal limits in both treatment groups. In summary, clozapine may carry a slightly higher but statistically insignificant risk of causing hyperglycemia. Overall, treatment with haloperidol or clozapine appears safe concerning liver and kidney function, as indicated by normal SGOT, SGPT, and urea levels.